FR-171113
FR171113 is a specific and non-peptide thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1 antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC50 of 0.29 μM..
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 173904-50-2
- Formule: C19H11Cl3N2O4S
- Masse moléculaire:469.73
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-14994
SCH79797 dihydrochloridePAR1 Antagonist -
HY-P1260
FSLLRY-NH2PAR2 Inhibitor -
HY-P1263
tcY-NH2PAR4 Antagonist -
HY-105999
APC 366Mast Cell Tryptase Inhibitor -
HY-P0078
TRAP-6PAR1 Agonist -
HY-108554
Q94 hydrochloridePAR1 Antagonist -
HY-13965
Parmodulin 2PAR1 Inhibitor -
HY-14350
AC-55541PAR Agonist -
HY-P1309A
PAR-4 Agonist Peptide, amide TFAPAR-4 Agonist -
HY-10119A
Vorapaxar sulfatePAR-1 Antagonist -
HY-138558
PAR-2-IN intermediate-1Drug Intermediate -
HY-P0226A
TFLLR-NH2TFAPAR1 Agonist
Activité biologique
Description
IC50 & Target
|
PAR1 .29 μM (IC50) |
In Vitro
FR171113 shows antiplatelet effect on the aggregation of guinea pig platelets induced by PAR1 agonist peptide and thrombin in vitro with IC50s of 1.5 and 0.35 μM, respectively[2].
FR171113 (0.032-1 μM) dose-dependently inhibits platelet aggregation induced by both thrombin and TRAP-6[1].
FR171113 significantly prevents the plasma-elicited up-regulation of RAGE, MCP-1 and ICAM-1 mRNA levels in HUVECs[2].
FR171113 (1 μM; pretreatment for 30 minutes) inhibits thrombin- and SFLLRN (human PAR1 agonist peptide)-induced ERK activation, but not factor Xa- or SLIGKV (PAR2 agonist peptide)-induced ERK activation, indicating that activation of ERK by factor Xa is specifically mediated by PAR2 in mesangial cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human washed platelets
-
Concentration:0.001, 0.01, 0.1, 1, 10, 100 μM
-
Incubation Time:
-
Result:The IC50 value for thrombin-induced platelet aggregation was 0.29 μM. The IC50 value for TRAP-6-induced platelet aggregation was 0.15 μM.
-
Cell Line:human umbilical vein endothelial cells (HUVECs)
-
Concentration:1 μM
-
Incubation Time:4 hours
-
Result:3% citrated human plasma-evoked ROS generation, RAGE, MCP-1 and ICAM-1 gene induction was significantly blocked.
-
Cell Line:Mesangial cells
-
Concentration:1 μM
-
Incubation Time:Pretreatment for 30 minutes
-
Result:Pretreatment inhibited thrombin (10 nM; for 5 minutes)- and SFLLRN(100 μM for 5 minutes)-induced ERK activation.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Hartley guinea pigs (650–950 g) were anesthetized with urethane (1.25 g/kg, i.p.)[4]
-
Dosage:0.32, 1.0, and 3.2 mg/kg
-
Administration:Administered subcutaneously (s.c.)
-
Result:Pretreatment with FR171113 prolonged this parameter in a dose-dependent manner. The time to thrombotic occlusion for 0.32, 1.0 and 3.2 mg/kg of FR171113 was 30.7±5.36, 44.7±8.41 and 92.6±9.79, respectively.
Chemical Information
-
CAS No. 173904-50-2
-
Masse moléculaire 469.73
-
Formule C19H11Cl3N2O4S
-
SMILES
O=C(OC)/C=C(S/C(N1C2=CC=C(Cl)C=C2)=N\C(C3=CC=C(Cl)C=C3Cl)=O)/C1=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Y Kato, et al. In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur J Pharmacol. 1999 Nov 19;384(2-3):197-202. [Content Brief]
[2]. Yuji Ishibashi, et al. Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovasc Diabetol. 2014 Mar 13;13:60. [Content Brief]
[3]. Misa Tanaka, et al. Role of coagulation factor Xa and protease-activated receptor 2 in human mesangial cell proliferation. Kidney Int. 2005 Jun;67(6):2123-33. [Content Brief]
[4]. Yasuko Kato, et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol. 2003 Jul 25;473(2-3):163-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
FR-171113 Related Classifications
HY-108555 Related Classifications
Powered by Bioz